L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re
A phase 2/3 trial of Cytarabine in acute myeloid leukaemia, run by Moleculin Biotech, Inc., now recruiting.
Overview
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML is a phase 2/3 interventional study registered as NCT06788756 by Moleculin Biotech, Inc., with 312 participants planned, started 2025-03-12 and due to reach its primary completion in 2029-08. Interventions recorded: Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.. Conditions listed: Acute Myeloid Leukaemia (AML). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TreatmentAmsacrine
Shares Cytarabine, Acute myeloid leukaemia.
- TrialA Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Shares Cytarabine, Acute myeloid leukaemia.
- TrialSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Shares Cytarabine, Acute myeloid leukaemia.
- TrialGalinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Shares Cytarabine, Acute myeloid leukaemia.
- TreatmentIdarubicin
Shares Cytarabine, Acute myeloid leukaemia.
- TrialA Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Shares Cytarabine, Acute myeloid leukaemia.
- TrialStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Shares Cytarabine, Acute myeloid leukaemia.
- TreatmentCPX-351 (liposomal daunorubicin-cytarabine)
Shares Cytarabine, Acute myeloid leukaemia.